POMC and COVID-19: Estimated use of non-tandard medications(treatments other than ACTH, oral steroid or vigabatrin) was rare in NorthAmerica (one respondent) but increased in Asia (from 1.5% [0, 20]prepandemic to 5% [0, 35] during the pandemic; P < .05).Higher COVID-19 burden correlated with greater use of oral steroids(P = .002) and vigabatrin (P = .005)but did not correlate with reduced use of ACTH (P = .39) orgreater use of non-standard first-line agents (P =.09).